🇺🇸 FDA
Patent

US 11141493

Compositions and methods for treating CEP290-associated disease

granted A61KA61K48/0008A61K48/0058

Quick answer

US patent 11141493 (Compositions and methods for treating CEP290-associated disease) held by Editas Medicine, Inc. expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K48/0008, A61K48/0058, A61K48/0066, A61K48/0091